Imaging biomarkers for Huntington’s disease can better inform clinical trial designs


  • Imaging biomarkers in people with Huntington’s Disease (HD) provide greater power of detection than clinical markers.

Why this matters

    Identification of imaging biomarkers for HD can lead to improved detection of disease stage, allowing for more tailored design in clinical trials.